Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Public ClinicalTrials.gov record NCT01728207. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Dose Escalation Study of Immunotherapy With IMMU-114 in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Study identification
- NCT ID
- NCT01728207
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Gilead Sciences
- Industry
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- IMMU-114 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2013
- Primary completion
- Feb 28, 2017
- Completion
- Feb 28, 2017
- Last update posted
- Aug 18, 2021
2013 – 2017
United States locations
- U.S. sites
- 5
- U.S. states
- 5
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Helen F Graham Cancer Center | Newark | Delaware | 19713 | — |
| Nancy N. and J.C. Lewis Cancer and Research Pavilion | Savannah | Georgia | 31405 | — |
| Indiana University Health Goshen Hospital | Goshen | Indiana | 46526 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43202 | — |
| Huntsman Cancer Institute, Univ. Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01728207, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 18, 2021 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01728207 live on ClinicalTrials.gov.